Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506422 | 0.80 | NPC1 (0.43) | LMNAALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13494304 | 0.80 | CTSS (0.43) | LMNANPC1PPARG | |
| SCHEMBL1929365 | 0.77 | BRD4 (0.46) | ALDH1A1SMN1; SMN2NPC1RAB9ABRD4 | |
| SCHEMBL5506152 | 0.77 | BRD4 (0.46) | ALDH1A1SMN1; SMN2NPC1RAB9ABRD4 | |
| SCHEMBL5758990 | 0.76 | GAA (0.52) | LMNATP53ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4359237 | 0.76 | KIF11 (0.53) | LMNATP53ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3849980 | 0.75 | KIF11 (0.53) | KIF11CYP3A4CYP2C19 | |
| SCHEMBL1384092 | 0.74 | KIF11 (0.60) | KIF11CYP3A4CYP2C19 | |
| SCHEMBL1384302 | 0.73 | KIF11 (0.42) | NPC1RAB9AKIF11BRD4CYP3A4 | |
| SCHEMBL13494316 | 0.72 | CTSL (0.47) | LMNAPPARGCYP3A4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | claimed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | claimed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | claimed |
| JP-4836280-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1765789-A1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060009472-A1 | Substituted imidazole derivatives | CHIRON CORPORATION | 2006-01-12 | — | — | US | claimed |
| WO-2006002236-A1 | N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | disclosed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | disclosed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1765789-A1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060009472-A1 | Substituted imidazole derivatives | CHIRON CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002236-A1 | N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009472-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | LMNA 4285/4885TP53 1337/4885ALDH1A1 408/4885 |
| US-20090258016-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | LMNA 4285/4885TP53 1337/4885ALDH1A1 408/4885 |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | ABCG2, CYP2C19, AADAC | LMNA 4285/4885TP53 1337/4885ALDH1A1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.